Cen Su1, Kangren Zhao1, Haiping Xia1, Yaoming Xu2. 1. Department of Neurology, The Fourth Hospital of Jiangsu University, Zhenjiang, China. 2. Department of Neurology, Tongliao Hospital of Inner Mongolia Autonomous Region, Tongliao, China.
Abstract
BACKGROUND: In the past few decades, it has been demonstrated with animal models and clinical studies that a chronic inflammatory process significantly contributes to Alzheimer's disease (AD) pathogenesis. METHODS: We systematically searched on PubMed and Web of Science for studies associated with peripheral inflammatory biomarkers in AD and mild cognitive impairment (MCI) before July 2018. Meta-analysis was conducted to summarise results of studies relative to peripheral cytokines and chemokines in AD and MCI. RESULTS: Mean (± SD) concentrations of peripheral inflammatory biomarkers for AD, MCI and healthy controls were extracted from these studies. Our meta-analysis revealed consistently elevated concentrations of inflammatory biomarkers such as C-reactive protein, interleukin-1β (IL-1β), IL-2, IL-6, IL-12, IL-18, monocyte chemotactic protein-1 (MCP-1), MCP-3, IL-8 and interferon-γ-inducible protein 10 in AD patients, whereas no consistent results were obtained for elevated concentrations of cytokines or chemokines except MCP-1 in MCI patients. CONCLUSIONS: In conclusion, these results provided evidence to support that systematic inflammation might be a biomarker for AD diagnosis, whereas it might be a later event during AD disease progression.
BACKGROUND: In the past few decades, it has been demonstrated with animal models and clinical studies that a chronic inflammatory process significantly contributes to Alzheimer's disease (AD) pathogenesis. METHODS: We systematically searched on PubMed and Web of Science for studies associated with peripheral inflammatory biomarkers in AD and mild cognitive impairment (MCI) before July 2018. Meta-analysis was conducted to summarise results of studies relative to peripheral cytokines and chemokines in AD and MCI. RESULTS: Mean (± SD) concentrations of peripheral inflammatory biomarkers for AD, MCI and healthy controls were extracted from these studies. Our meta-analysis revealed consistently elevated concentrations of inflammatory biomarkers such as C-reactive protein, interleukin-1β (IL-1β), IL-2, IL-6, IL-12, IL-18, monocyte chemotactic protein-1 (MCP-1), MCP-3, IL-8 and interferon-γ-inducible protein 10 in ADpatients, whereas no consistent results were obtained for elevated concentrations of cytokines or chemokines except MCP-1 in MCI patients. CONCLUSIONS: In conclusion, these results provided evidence to support that systematic inflammation might be a biomarker for AD diagnosis, whereas it might be a later event during AD disease progression.
Authors: Clara Ballerini; Alfred K Njamnshi; Sharon L Juliano; Rajesh N Kalaria; Roberto Furlan; Rufus O Akinyemi Journal: Front Immunol Date: 2022-06-13 Impact factor: 8.786
Authors: Reesha R Patel; Florence P Varodayan; Melissa A Herman; Vanessa Jimenez; Rebecca Agnore; Lina Gao; Michal Bajo; Verginia C Cuzon Carlson; Nicole A Walter; Suzanne S Fei; Kathleen A Grant; Marisa Roberto Journal: Neuropsychopharmacology Date: 2021-11-26 Impact factor: 8.294
Authors: Grace E Weber; Maria Khrestian; Elizabeth D Tuason; Yvonne Shao; Jagan Pillai; Stephen Rao; Hao Feng; Yadi Zhou; Feixiong Cheng; Tara M DeSilva; Shaun Stauffer; James B Leverenz; Lynn M Bekris Journal: J Immunol Date: 2022-05-06 Impact factor: 5.426
Authors: Cutter A Lindbergh; Breton M Asken; Kaitlin B Casaletto; Fanny M Elahi; Lauren A Goldberger; Corrina Fonseca; Michelle You; Alexandra C Apple; Adam M Staffaroni; Ryan Fitch; Will Rivera Contreras; Paul Wang; Anna Karydas; Joel H Kramer Journal: J Gerontol A Biol Sci Med Sci Date: 2021-10-13 Impact factor: 6.591